You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Johnson and Johnson
Merck
Boehringer Ingelheim
McKinsey

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR QAW039


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Clinical Trials for QAW039

Trial ID Title Status Sponsor Phase Summary
NCT01253603 Efficacy, Safety, and Pharmacokinetics of QAW039 Completed Novartis Pharmaceuticals Phase 2 This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.
NCT01437735 Dose Finding Study for QAW039 in Asthma Completed Novartis Pharmaceuticals Phase 2 This study aims to demonstrate a clinically significant improvement in Forced Expiratory Volume in one second (FEV1) in moderate to severe allergic asthmatics inadequately controlled by Inhaled Corticosteroid (ICS) therapy. Patients will be treated with QAW039, an active comparator, or placebo. This will be a randomized, placebo-controlled, dose-ranging, multi-centre trial.
NCT01545726 Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma Completed Novartis Pharmaceuticals Phase 2 This study will assess the safety and efficacy of QAW039 when added to current therapy in patients that have sputum eosinophilia and persistent asthma.
NCT01785602 Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis. Completed Novartis Pharmaceuticals Phase 2 The purpose of this study is to determine whether QAW039 is safe and has beneficial effects in people who have moderate to severe atopic dermatitis (AD).
NCT01804400 A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber Completed Novartis Pharmaceuticals Phase 2 This study will assess the safety and efficacy of QAW039 alone and in combination with Montelukast in patients with allergic rhinitis (hay fever) using an environmental exposure chamber.
NCT01836471 A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients Completed Novartis Pharmaceuticals Phase 2 The purpose of the study is to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.
NCT02555683 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Recruiting Novartis Pharmaceuticals Phase 3 This study aims to determine the efficacy and safety of QAW039 (Dose 1 and Dose 2), compared with placebo, when added to GINA steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2015) in each of the groups (patients with severe asthma and high eosinophil counts and all patients with severe asthma).
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for QAW039

Condition Name

Condition Name for
Intervention Trials
Asthma 12
Bronchial Diseases 2
Physiological Effects of Drugs 2
Hypersensitivity 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Asthma 12
Eosinophilia 3
Lung Diseases 2
Hypersensitivity 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for QAW039

Trials by Country

Trials by Country for
Location Trials
United States 93
Japan 42
Italy 18
India 17
Argentina 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
California 9
Georgia 6
Florida 6
Texas 6
North Carolina 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for QAW039

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 4 1
Phase 3 6
Phase 2 9
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Not yet recruiting 7
Completed 6
Recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for QAW039

Sponsor Name

Sponsor Name for
Sponsor Trials
Novartis Pharmaceuticals 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Harvard Business School
McKinsey
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.